Ni, Kaiyuan http://orcid.org/0000-0002-8152-6746
Lan, Guangxu http://orcid.org/0000-0002-0415-5849
Veroneau, Samuel S.
Duan, Xiaopin
Song, Yang
Lin, Wenbin http://orcid.org/0000-0001-7035-7759
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01–CA198989, 1R01CA216436)
Article History
Received: 3 June 2018
Accepted: 12 September 2018
First Online: 17 October 2018
Competing interests
: W.L. is founder of RiMO Therapeutics, which licensed the nMOF technology from the University of Chicago. The remaining authors declare no competing interests.